Been a tough industry and tough company to own. Has been in the crosshairs of some of the regulators in Washington but the business is sound. It's home healthcare. People would rather be treated at home than in hospital and it's cheaper. Will probably earn over $4 a share this year, which is pretty attractive.
Healthcare company involved in home healthcare. Has done very well and will continue to do so. Was held back because of fears of the US government changes in healthcare. Extremely well managed and trading at only 8X earnings.
Home health care company for acute patients. Contributor to health care reform. Least expensive option for health care. Stock suffered from the overhang of health care reform. Recently doubled his position as a result of management changes and skittish market.
(A Top Pick Feb 17/10. Down 40.3%.) Likes the home health care industry. Difficulty is the unknown regarding government reimbursement act, which is still up in the air. Very volatile.
Your Watchlist
Add stocks to watchlist to monitor them daily and get important alerts.